Corporate Profile
ASKA Pharmaceutical Holdings Co., Ltd.

100 Years

ASKA’s First

2021and Onward

Formation of ASKA
PharmaceuticalHoldings Co., Ltd.

2020

Further advancing operations
Relocated the Kawasaki Research Center tothe Shonan Health Innovation Park (ShonaniPark) to strengthen its drug discovery
functions in order to further step up
operations.

2013

Formation of ASKA Animal HealthCo., Ltd.
Established through a spin-off of ASKA’s animal
health business (formerly Teikoku Hormone
Mfg. Co., Ltd.). Conducts business under thethemes of breeding, immunity and nutrition.

1980

1993

Formation of ASKA Pharma MedicalCo., Ltd.
Established under the current name after a merger
with predecessor company Medical System Service
Kanagawa Co., Ltd.
In 2020, moved to the Shonan Health Innovation
Park (Fujisawa-shi, Kanagawa Prefecture) andbegan specializing in the testing business.

Diversification of management andlaunch of major new products
Listed on theFirst Section of theTokyo Stock Exchange

19202020

2008

Enhanced our position as a specialty pharmacompany focused on the three core areas ofinternal medicine, obstetrics and gynecology (Ob/Gyn), and urology. Also involved in clinical testing,pharmaceutical raw materials, food, medical
devices and other businesses. Opened the Iwaki
Factory in 1980. Established the International
Representative Office in Frankfurt, Germany in 1997.

2005

Merged with Grelan Pharmaceutical Co., Ltd.
in 2005 to form ASKA Pharmaceutical Co., Ltd.
Strengthened new drug development andmade a full-scale move into the generics
business.

1955

Established a business foundation
and went publicFounder Yasohachi Yamaguchi established
Teikoku Hormone Research Institute in
Minamiyoshidacho, Yokohama in 1920. Began
research, manufacture and sale of hormone
preparations based on the unique idea ofcreating useful medicines from animal organs.
Established the Takatsu Factory (formerly theKawasaki Research Center) in 1936.

After the Second World War, the head officeand factory, which had been destroyed in thewar, were rebuilt under a new organizational
structure. Developed and launched a series of
new products utilizing new research andproduction facilities and an enhanced sales
structure. Entered the veterinary medicine
business. Listed shares on the Tokyo Stock
Exchange in 1955.

Origins in research,
manufacture and sale ofhormone preparations

Established Mint+ Health Lab for Womenas part of ASKA’s social contribution
activities to commemorate its
100th anniversary.

Formation of ASKA PharmaceuticalCo., Ltd.

Founded as a pharmaceuticalcompany

1920“Knowing yourself,is protecting yourself”

ASKA’s History
Over the more than 100 years since the founding of ASKA, it has developed andexpanded its business as a pioneer in hormone preparations. ASKA has adopted
a holding company structure that includes its businesses in pharmaceuticals(ASKA Pharmaceutical), veterinary medicines (ASKA Animal Health) and testing(ASKA Pharma Medical), and will continue to contribute to society as it evolves
into a total healthcare company.

In aiming to become a total
healthcare company, we willaddress the changing environmentof the pharmaceutical industry
and improve our corporate value.

Corporate Philosophy
Contribute toward theimprovement of people’s
health and progress insociety through thedevelopment of innovative
products

ASKA
PharmaceuticalCo., Ltd.

ASKA
Pharmaceutical
Holdings Co., Ltd.

ASKA Pharma
Medical Co., Ltd.

ASKA Animal
Health Co., Ltd.

Further development and growth under a holding company
structure to improve corporate value
In April 2021, we transitioned to a holding company structure and made anew start as ASKA Pharmaceutical Holdings Co., Ltd.
The shift to a holding company structure will facilitate the creation ofa flexible organization and swift decision-making in addition to further
strengthening our governance system, thus achieving greater sustainablegrowth for the entire ASKA Group.
ASKA Pharmaceutical Holdings Co., Ltd. aims to become a total healthcarecompany with a strong foundation as a specialty pharma company. We willconduct operations in Japan and overseas centered on our existing businesses
spanning the entire healthcare market, from prevention, testing and diagnostics
to treatment and prognosis.
We would appreciate your continued understanding and support of ASKA
Pharmaceutical Holdings Co., Ltd. as it continues to take on various challenges.

Takashi Yamaguchi
President, Representative Director
ASKA Pharmaceutical Holdings Co., Ltd.

ASKA PharmaceuticalContributing to the Improvement of People’s Health and Quality of Life
as a Pioneer in Hormone Preparations
ASKA Pharmaceutical Co., Ltd., our main subsidiary,
conducts business in three core areas with a focus onpharmaceuticals, particularly hormone preparations.
By staying attuned to women’s life stages andchanging lifestyles, we remain a leading company inthe field of obstetrics and gynecology (Ob/Gyn) witha broad lineup of products including uterine fibroids
and endometriosis agents and dysmenorrhea agentsto protect women’s health as they lead active,
healthy daily lives. We have launched Mint+ HealthLab for Women’s health with the key message of“Knowing yourself, is protecting yourself” andconduct activities to raise awareness of various
symptoms and diseases.
In the field of internal medicine, for nearly acentury we have continued to market and further
develop the hypothyroidism agent we launched in
1922. In addition, the hepatic encephalopathy
agent we launched as an orphan drug in 2016 islisted as a recommended drug in the Japanese
Evidence-Based Clinical Practice Guidelines for
Cirrhosis. Both pharmaceuticals have continued tomeet medical needs.
Through our ongoing efforts to leverage ourhigh degree of specialization to enhance ourdevelopment pipeline, provide a stable supply ofhigh-quality pharmaceuticals, and collect andprovide appropriate information, we focus ondelivering reliable value to society by contributing
to the improvement of people’s health and qualityof life.

InternalMedicine(Gastroenterology andThyroid)

Ob/GynUrology

ASKA Animal Health

ASKA Pharma
MedicalContributing to the Creation of a Society
Where People and Animals Can Coexist

Contributing to a Healthy Society throughCutting-Edge Measurement Techonologies

Livestock andFisheriesCompanion Animal
HealthASKA Animal Health Co., Ltd. plays a significant role insupporting farmers and veterinary professionals.
We strive to maintain or improve the productivity ofthe livestock and fishery products that are essential for
Japan’s food self-sufficiency by conducting research,development, manufacturing, import, and sales ofveterinary medicines and other products that help tomaintain the health of companion animals, such asdogs and cats.
In the field of livestock and fisheries, our focus lies
on our strengths in breeding, immunity, and nutrition.
We aim to help enhance the productivity of livestockand fisheries by utilizing our main products, including
hormone preparations for breeding and amino acids.
Consumers’ foremost need is for product safety.
We are committed to our corporate philosophy ofcontributing to the creation of a society wherepeople and animals can coexist in harmony. To achievethis, we will continue with our untiring efforts toensure that consumers can eat their food with peaceof mind.

Microdeterminationof Endogenous
Hormones

Measurements Using
Non-Invasive Samples(Hair, nails, etc.)

ASKA Pharma Medical Co., Ltd. leverages its advanced
technologies and extensive know-how to contribute toa wide range of fields including basic research, clinicalresearch and diagnostics, centered on measurementof steroid hormones and other bioactive substances(testing business). We conduct measurement on
consignment of various specimens in line withcustomer needs, utilizing a liquid chromatographytandem mass spectrometry (LC-MS/MS) measurement
method with improved accuracy and sensitivity. Thismethod was developed using our original technology.
The technologies that measure trace amounts from
non-invasive, self-collectable samples, such as hairand fingernails, can lower the hurdle to testing. This,
we believe, can contribute to higher screening rates.
As preventive medicine and measures to improvepre-symptomatic conditions grow in importance,
testing needs are diversifying and high-precision
testing is required in a wider range of fields. By
earnestly addressing these needs, we aim to enhance
our corporate value.

Sustainability at ASKA Pharmaceutical Holdings
Our mission is to serve stakeholders and to help
achieve a sustainable society through activities from an
ESG perspective based on the United Nations’Sustainable Development Goals (SDGs), as a total
healthcare company centered on providing
pharmaceuticals that meet contemporary needs as wellas veterinary pharmaceuticals and testing businesses.
When we transitioned to a holding company
structure, we also established an ESG Committee. Westrive to examine the material issues being dealt withthroughout the ASKA Group and make every effort toachieve our corporate philosophy, improve corporate
value over the medium to long term, and deepen ourrelationships of trust with stakeholders.

Patients and medical professionals
We provide a stable supply of high-quality pharmaceuticals and conduct
appropriate activities to provide pharmaceutical information. We also
make wide-ranging contributions to society through our innovative andoriginal medicines.

Employees

Customers

We believe that our humanresources are the driving force
behind our corporate
activities. We ensure aharmonious workplaceenvironment with respect todiversity – it is a place whereemployees can work withpeace of mind and fully
demonstrate their capabilities.

To maintain sound, healthy
relationships with ourcustomers, we strive to
conduct business on an equal
footing and avoid causing
unreasonable losses.

Local communities
We promote environmental conservation andcommunication with local communities to be agood corporate citizen that is trusted by society.

Shareholders and investors
We disclose information in a timely, fair andappropriate manner, and strive for stable
returns on profits. We also ensure thesoundness of our management and work tocontinuously improve corporate value.

Main SDGs Addressed by ASKA Pharmaceutical Holdings
In working to achieve our corporate philosophy to “Contribute toward the improvement of people’s health and progress insociety through the development of innovative products,” we address niche medical needs, mainly for products, research andother activities in fields related to hormones. We aim for sustainable growth through research, manufacture and sale ofpharmaceuticals and veterinary pharmaceuticals and hormone testing research and outsourcing services.
To achieve a society and become an enterprise free from discrimination of all types, we create workplaces in each Group company
that protect the dignity of all employees as they display their potential to the fullest. In particular, by providing high-quality
hormone preparations and other products, our pharmaceutical manufacturing operations help to improve quality of life forwomen through support for their life planning and reproductive health.

In all our business activities, we work to reduce energy consumption, promote reduction and reuse of waste, and control
emissions of air and water pollutants, chemicals and other substances with the aim of protecting the environment andcontinuously reducing our environmental load.

We work to continuously strengthen our quality assurance and safety monitoring systems at each Group company to maintainhigh quality and stable supply. We achieve this through research, manufacturing and sale of pharmaceuticals and veterinary
pharmaceuticals and hormone testing research and outsourcing services.

We work to improve the productivity of the livestock and fishery products that underpin Japan’s food self-sufficiency through thesale of veterinary pharmaceuticals and feed additives under the themes of breeding, immunity and nutrition. We support farmers
and veterinary professionals nationwide by providing high-purity, high-quality products that use reproductive hormone
preparations and amino acids.
We strive to maintain a balance between management supervision and business execution, and ensure shareholders’ rights arerespected through transparent, fair, prompt, and decisive decision-making. While taking autonomous actions to achievesustainable growth and enhance corporate value over the medium to long term, we will contribute to the development of theGroup, investors, and the economy as a whole.
We work to enhance our development pipeline by promoting research alliance activities and research and development activities
in cooperation with academia and external organizations and collaboration among industry, government and academia. We use
hormone-related substances, which are deeply rooted in ASKA’s history, to develop better medicines and treatments that resolve
issues for healthy lifestyles in areas such as improvement of quality of life and preventive medicine.

Group Companies
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Co., Ltd.
5 -1, Shibaura 2-chome, Minato-ku, Tokyo 108-8532, Japan

ASKA Animal Health Co., Ltd.

ASKA Pharma Medical Co., Ltd.

5-1, Shibaura 2-chome, Minato-ku,
Tokyo 108-8532, Japan

Shonan Health Innovation Park, 26-1,
Muraoka-Higashi 2-chome, Fujisawashi, Kanagawa 251-8555, Japan

5-1, Shibaura 2-chome, Minato-ku,
Tokyo 108-8532, Japan
Tel: +81-3-5484-8845
https://www.aska-pharma-hd.co.jp/english/

Produced in July 2021
Revised in February 2024